Supporting evidence for using biomarkers in the diagnosis of MCI due to AD

Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:270–279 American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, USA Arai H, Terajima M, Miura M et al (1995) Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer’s disease. Ann Neurol 38:649–652 Bennett DA, Wilson RS, Schneider JA et al (2002) Natural history of mild cognitive impairment in older persons. Neurology 59:198–205 Bian H, Van Swieten JC, Leight S et al (2008) CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70:1827–1835 Bibl M, Mollenhauer B, Lewczuk P et al (2011) Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias. Dement Geriatr Cogn Disord 31:37–44 Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18:351–357 Braak H, Del Tredici K (2011) The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol 121:171–181 Caroli A, Prestia A, Chen K, EADC-PET Consortium, NEST-DD, and Alzheimer’s Disease Neuroimaging Initiative et al (2012) Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J Nucl Med 53:592–600 Clark CM, Xie S, Chittams J et al (2003) Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60:1696–1702 Cummings JL, Mega M, Gray K et al (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308–2314 De Leo D, Frisoni GB, Rozzini R, Trabucchi M (1993) Italian community norms for the brief symptom inventory in the elderly. Br J Clin Psychol 32:209–213 De Souza LC, Lamari F, Belliard S et al (2012) Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer’s disease from other cortical dementias. J Neurol Neurosurg Psychiatry 82:240–246 Edison P, Rowe CC, Rinne JO et al (2008) Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C] PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79:1331–1338 Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198 Frisoni GB, Pievani M, Testa C et al (2007) The topography of grey matter involvement in early and late onset Alzheimer’s disease. Brain 130:720–730 Frisoni GB, Prestia A, Zanetti O et al (2009) Markers of Alzheimer’s disease in a population attending a memory clinic. Alzheimers Dement 5:307–317 Galluzzi S, Geroldi C, Ghidoni R et al (2010) The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. J Neurol 257:2004–2014 Galluzzi S, Testa C, Boccardi M et al (2009) The Italian brain normative archive of structural MR scans: norms for medial temporal atrophy and white matter lesions. Aging Clin Exp Res 21:266–276 Ghidoni R, Benussi L, Paterlini A et al (2011) Cerebrospinal fluid biomarkers for Alzheimer’s disease: the present and the future. Neurodegener Dis 8:413–420 Ghidoni R, Paterlini A, Albertini V et al (2011) A window into the heterogeneity of human cerebrospinal fluid Aβ peptides. J Biomed Biotechnol 2011:697036 Hampel H, Burger K, Teipel SJ et al (2008) Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease. Alzheimers Dement 4:38–48 Herholz K, Salmon E, Perani D et al (2002) Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17:302–316 Hoffman JM, Welsh-Bohmer KA, Hanson M et al (2000) FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 41:1920–1928 Ingelsson M, Fukumoto H, Newell KL et al (2004) Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62:925–931 Jack CR Jr, Petersen RC, Xu Y et al (2000) Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 55:484–489 Jack CR Jr, Lowe VJ, Weigand SD, Alzheimer’s Disease Neuroimaging Initiative et al (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain 132:1355–1365 Jack CR Jr, Knopman DS, Jagust WJ et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 9:119–128 Lawton MP, Brody EM (1969) Assessment of older people: self maintaining and instrumental activities of daily living. Gerontologist 9:179–186 Lezak M, Howieson D, Loring DW (2004) Neuropsychological assessment, 4th edn. University Press, Oxford Mayeux R, Small SA, Tang M et al (2001) Memory performance in healthy elderly without Alzheimer’s disease: effects of time and apolipoprotein-E. Neurobiol Aging 22:683–689 McKeith IG, Galasko D, Kosaka K et al (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124 McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology 34:939–944 McKhann GM, Albert MS, Grossman M et al (2001) Work group on frontotemporal dementia and pick’s disease clinical and pathological diagnosis of frontotemporal dementia: report of the work group on frontotemporal dementia and pick’s disease. Arch Neurol 58:1803–1809 McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269 Seelaar H, Rohrer JD, Pijnenburg YA et al (2011) Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry 82:476–486 Sjogren M, Vanderstichele H, Agren H et al (2001) Tau and Abeta42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. Clin Chem 47:1776–1781 Strozyk D, Blennow K, White LR et al (2003) CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60:652–656 Wahlund LO, Barkhof F, Fazekas F et al (2001) European task force on age-related white matter changes. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32:1318–1322 Whitwell JL, Wiste HJ, Weigand SD, for the Alzheimer Disease Neuroimaging Initiative et al (2012) Comparison of imaging biomarkers in the Alzheimer disease neuroimaging initiative and the mayo clinic study of aging. Arch Neurol 69:614–622 Womack KB, Diaz-Arrastia R, Aizenstein HJ et al (2011) Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors. Arch Neurol 68:329–337